HK1172031A1 - 作為葡萄糖神經醯胺合成酶抑制劑的非結晶及結晶形式的 半酒石酸鹽 - Google Patents

作為葡萄糖神經醯胺合成酶抑制劑的非結晶及結晶形式的 半酒石酸鹽

Info

Publication number
HK1172031A1
HK1172031A1 HK12112977.8A HK12112977A HK1172031A1 HK 1172031 A1 HK1172031 A1 HK 1172031A1 HK 12112977 A HK12112977 A HK 12112977A HK 1172031 A1 HK1172031 A1 HK 1172031A1
Authority
HK
Hong Kong
Prior art keywords
genz
hemitartrate
amorphous
inhibitor
crystalline form
Prior art date
Application number
HK12112977.8A
Other languages
English (en)
Inventor
Hanlan Liu
Chris Willis
Renu Bhardwaj
Diane P Copeland
Abizer Harianawala
Jeffrey Skell
John Marshall
Jianmei Kochling
Gerard Palace
Judith Peterschmitt
Craig Siegel
Seng Cheng
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1172031(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of HK1172031A1 publication Critical patent/HK1172031A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
HK12112977.8A 2009-11-27 2012-12-14 作為葡萄糖神經醯胺合成酶抑制劑的非結晶及結晶形式的 半酒石酸鹽 HK1172031A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26474809P 2009-11-27 2009-11-27
PCT/US2010/057952 WO2011066352A1 (en) 2009-11-27 2010-11-24 An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase

Publications (1)

Publication Number Publication Date
HK1172031A1 true HK1172031A1 (zh) 2013-04-12

Family

ID=43431870

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15103822.1A HK1203485A1 (zh) 2009-11-27 2012-12-14 在組合療法中治療戈謝病或法布里病的
HK12112977.8A HK1172031A1 (zh) 2009-11-27 2012-12-14 作為葡萄糖神經醯胺合成酶抑制劑的非結晶及結晶形式的 半酒石酸鹽

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15103822.1A HK1203485A1 (zh) 2009-11-27 2012-12-14 在組合療法中治療戈謝病或法布里病的

Country Status (41)

Country Link
US (6) US11458119B2 (zh)
EP (5) EP2796457B1 (zh)
JP (6) JP2013512252A (zh)
KR (5) KR20120115972A (zh)
CN (5) CN105777707B (zh)
AR (3) AR079152A1 (zh)
AU (3) AU2010324810B2 (zh)
BR (1) BR112012012947B8 (zh)
CA (3) CA2781676C (zh)
CL (2) CL2012001348A1 (zh)
CR (1) CR20120277A (zh)
CY (3) CY1115880T1 (zh)
DK (3) DK2504332T4 (zh)
DO (2) DOP2012000141A (zh)
EA (3) EA029990B1 (zh)
EC (2) ECSP12011926A (zh)
ES (4) ES2754398T3 (zh)
GT (1) GT201200161A (zh)
HK (2) HK1203485A1 (zh)
HR (3) HRP20140780T4 (zh)
HU (2) HUE045784T2 (zh)
IL (4) IL310635A (zh)
LT (2) LT2796457T (zh)
MA (1) MA33838B1 (zh)
ME (1) ME02477B (zh)
MX (1) MX358345B (zh)
MY (2) MY160542A (zh)
NI (1) NI201200096A (zh)
NZ (3) NZ625712A (zh)
PE (2) PE20121337A1 (zh)
PH (1) PH12015502514A1 (zh)
PL (4) PL3133070T3 (zh)
PT (4) PT2796457T (zh)
RS (3) RS53503B2 (zh)
SG (2) SG10201800136QA (zh)
SI (3) SI3133070T1 (zh)
SM (1) SMT201600273B (zh)
TN (1) TN2012000237A1 (zh)
TW (3) TWI606827B (zh)
UA (1) UA113491C2 (zh)
WO (1) WO2011066352A1 (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
CN105777707B (zh) 2009-11-27 2020-10-13 基酶有限公司 作为葡糖神经酰胺合酶的抑制剂的无定型和结晶形式的Genz 112638半酒石酸盐
WO2012177778A1 (en) * 2011-06-20 2012-12-27 Mount Sinai School Of Medicine Anti-tnf- therapy for the mucopolysaccharidoses and other lysosomal disorders
HUE051021T2 (hu) 2011-09-07 2021-01-28 Sinai School Medicine Ceramidáz és sejtek differenciálódása
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
CN104582770B (zh) 2012-06-01 2019-01-29 西奈山伊坎医学院 在感染的治疗和预防中的神经酰胺水平
HUE046113T2 (hu) 2013-03-14 2020-02-28 Icahn School Med Mount Sinai Terápiás sav ceramidáz készítmények és azok elõállítási és felhasználási eljárásai
JP6537500B2 (ja) * 2013-09-20 2019-07-03 ビオマリン プハルマセウトイカル インコーポレイテッド 疾患治療用のグルコシルセラミドシンターゼ阻害剤
CA2954030A1 (en) * 2014-07-03 2016-01-07 Dr. Reddy's Laboratories Limited Amorphous form of eliglustat hemitartarate
WO2016166170A1 (en) 2015-04-14 2016-10-20 Sandoz Ag Crystalline eliglustat hydrochloride
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US11116755B2 (en) 2015-11-18 2021-09-14 Genzyme Corporation Biomarker of polycystic kidney disease and uses thereof
CN107445938B (zh) * 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
ZA201803719B (en) 2017-06-05 2019-04-24 Cipla Ltd Stable solid dispersions of eliglustat hemitartrate
WO2018232235A1 (en) 2017-06-16 2018-12-20 Beta Pharma, Inc. Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
US20200222310A1 (en) * 2017-08-08 2020-07-16 Kashiv Biosciences, Llc Pharmaceutical composition comprising eliglustat
US20200197366A1 (en) * 2017-08-08 2020-06-25 Kashiv Biosciences, Llc Pharmaceutical composition comprising eliglustat
IL275091B1 (en) 2017-12-15 2024-05-01 Genzyme Corp Methods for treating Gaucher's disease
WO2019123476A1 (en) * 2017-12-20 2019-06-27 Sarudbhava Formulations Private Limited Stable amorphous eliglustat premix and process for the preparation thereof
US11760741B2 (en) 2018-05-02 2023-09-19 Kashiv Biosciences, Llc Pro-drugs of eliglustat
JP2021525711A (ja) * 2018-05-27 2021-09-27 バイオアシス テクノロジーズ インコーポレイテッド ゴーシェ病の処置
CN110878079A (zh) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 一种高纯度依利格鲁司他的制备方法
CN116120274A (zh) * 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
HUT73527A (en) 1993-08-13 1996-08-28 Seikagaku Kogyo Co Ltd Remedy for nervous diseases
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
CA2182485A1 (en) 1994-02-02 1995-08-10 Yong Wei Pharmaceutically active compounds and liposomes, and methods of use thereof
JP3850437B2 (ja) 1994-06-10 2006-11-29 生化学工業株式会社 ２−アシルアミノプロパノール化合物及び医薬組成物
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US6890949B1 (en) 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US5916911A (en) 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP3993908B2 (ja) 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
EP1098642B1 (en) 1998-07-27 2007-04-04 Johns Hopkins University Diamino-propanol-compounds for treating ischemia
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
CA2378600A1 (en) * 1999-07-09 2001-01-18 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
NZ519984A (en) * 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US20040252299A9 (en) 2000-01-07 2004-12-16 Lemmo Anthony V. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
JP2003531173A (ja) 2000-04-24 2003-10-21 テバ ファーマシューティカル インダストリーズ リミティド ゾルピデムヘミタートレイト
US6436987B1 (en) 2000-06-08 2002-08-20 Pfizer Inc. Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP2004531478A (ja) 2001-01-10 2004-10-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アミノセラミド様化合物および治療目的での使用方法
KR20030067755A (ko) * 2001-01-18 2003-08-14 메르크 파텐트 게엠베하 글루코세레브로시다제 활성을 갖는 이관능성 융합 단백질
PT2067775E (pt) 2001-07-16 2012-07-16 Genzyme Corp Inibidor de n-acil-esfingosina-glucosiltransferase
EP1281755A3 (en) 2001-07-31 2003-06-18 Pfizer Products Inc. Variants of the human cyp2d6 gene
ATE539062T1 (de) 2001-08-08 2012-01-15 Tobira Therapeutics Inc Bizyklishe verbindung, ihre herstellung und verwendung
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
WO2004004702A2 (en) 2002-07-09 2004-01-15 The Scripps Research Institute Method to inhibit ischemia and reperfusion injury
US20050032070A1 (en) 2003-08-05 2005-02-10 Sebastian Raimundo Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
EP1709053B1 (en) * 2004-01-27 2011-04-06 Synthon B.V. Stable salts of olanzapine
JP2008514731A (ja) 2004-09-30 2008-05-08 ヴァンダ ファーマシューティカルズ インコーポレイテッド イロペリドンの投与方法
US8324230B2 (en) 2004-10-13 2012-12-04 Pfizer Inc. Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-Yl]-N-(2-hydroxyethyl)-4-methylbenzamide
JP2008519840A (ja) * 2004-11-10 2008-06-12 ジェンザイム・コーポレイション 糖尿病の処置方法
US20070088082A1 (en) * 2005-09-28 2007-04-19 Judith Aronhime Polymorphic forms of ladostigil tartrate
EP1948655A1 (en) * 2005-10-03 2008-07-30 Mallinckrodt, Inc. Process for preparing zolpidem hemitartrate and tartrate polymorphs
MX2007016179A (es) 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
HUE026057T2 (en) 2006-05-09 2016-05-30 Genzyme Corp Procedures for the Treatment of Fatty Liver Disease, which comprises inhibition of glycosphingolipid synthesis
KR101271225B1 (ko) 2006-10-31 2013-06-03 삼성디스플레이 주식회사 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법
TWI314226B (en) 2006-12-07 2009-09-01 Ind Tech Res Inst Piezoelectricity-driving optical lens module
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
AU2008232614A1 (en) 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Method for the treatment of Fabry disease using pharmacological chaperones
WO2008134628A2 (en) * 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2594564B1 (en) * 2007-05-31 2016-09-28 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
DE102007029581B4 (de) 2007-06-26 2020-04-09 GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) Kraftfahrzeugdach und Kraftfahrzeugkarosserie
AU2009226083A1 (en) 2008-03-19 2009-09-24 Existence Genetics Llc Genetic analysis
WO2009117150A2 (en) 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
BR112012012641A2 (pt) 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
CN105777707B (zh) 2009-11-27 2020-10-13 基酶有限公司 作为葡糖神经酰胺合酶的抑制剂的无定型和结晶形式的Genz 112638半酒石酸盐
CA2936852C (en) 2009-11-27 2019-10-29 Adverio Pharma Gmbh Method for producing methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate and its purification for use thereof as pharmaceutical substance
JP2014517049A (ja) 2011-06-21 2014-07-17 ノバルティス アーゲー （ｓ）−ピロリジン−１，２−ジカルボン酸２−アミド１−（｛４−メチル−５−［２−（２，２，２−トリフルオロ−１，１−ジメチル−エチル）−ピリジン−４−イル］−チアゾール−２−イル｝−アミドの多形
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
JP6728842B2 (ja) 2016-03-24 2020-07-22 オムロン株式会社 光学計測装置
CN107445938B (zh) 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof

Also Published As

Publication number Publication date
EA029990B1 (ru) 2018-06-29
HK1203485A1 (zh) 2015-10-30
ES2493940T5 (es) 2021-11-23
SG10201407881WA (en) 2015-01-29
PT3133070T (pt) 2019-11-11
US20230172903A1 (en) 2023-06-08
KR20120115972A (ko) 2012-10-19
CN102712629B (zh) 2016-10-12
EP3599237A1 (en) 2020-01-29
AU2010324810B2 (en) 2016-05-12
CN105753846A (zh) 2016-07-13
HRP20161038T1 (hr) 2016-10-21
PT2796457T (pt) 2016-07-14
EA201890254A3 (ru) 2019-02-28
ME02477B (me) 2017-02-20
CY1117996T1 (el) 2017-05-17
CN112521367A (zh) 2021-03-19
JP7150528B2 (ja) 2022-10-11
TWI656873B (zh) 2019-04-21
CL2012001348A1 (es) 2012-08-24
EP3133070A1 (en) 2017-02-22
EP2504332B1 (en) 2014-06-04
EP3896069A1 (en) 2021-10-20
PE20171255A1 (es) 2017-08-28
TN2012000237A1 (en) 2013-12-12
NZ625712A (en) 2016-02-26
PE20121337A1 (es) 2012-10-12
EA201890254A2 (ru) 2018-10-31
NI201200096A (es) 2012-10-30
SI3133070T1 (sl) 2019-11-29
KR20220162824A (ko) 2022-12-08
ES2493940T3 (es) 2014-09-12
UA113491C2 (xx) 2017-02-10
DK2504332T4 (da) 2021-06-07
SI2504332T1 (sl) 2014-09-30
SI2504332T2 (sl) 2021-08-31
BR112012012947B8 (pt) 2021-05-25
JP2015212291A (ja) 2015-11-26
CN105777707B (zh) 2020-10-13
PL2504332T3 (pl) 2014-10-31
MY160542A (en) 2017-03-15
CN102712629A (zh) 2012-10-03
RS53503B2 (sr) 2021-07-30
AR121611A2 (es) 2022-06-22
CN105777707A (zh) 2016-07-20
LT3133070T (lt) 2019-11-11
HRP20191647T1 (hr) 2019-12-13
WO2011066352A8 (en) 2011-08-11
DK2796457T3 (en) 2016-08-29
JP2013512252A (ja) 2013-04-11
CA3075788C (en) 2021-12-21
NZ715108A (en) 2017-06-30
RS54978B1 (sr) 2016-11-30
BR112012012947A2 (pt) 2017-03-01
LT2796457T (lt) 2016-09-12
EP3133070B1 (en) 2019-08-14
PL3599237T3 (pl) 2021-09-27
EA201592195A1 (ru) 2016-04-29
MY192644A (en) 2022-08-29
US11458119B2 (en) 2022-10-04
AU2017265180B2 (en) 2019-08-01
NZ600155A (en) 2014-10-31
HUE045784T2 (hu) 2020-01-28
IL310635A (en) 2024-04-01
ES2875382T3 (es) 2021-11-10
RS53503B1 (en) 2015-02-27
CN112521366A (zh) 2021-03-19
MA33838B1 (fr) 2012-12-03
KR20200013105A (ko) 2020-02-05
AU2010324810A1 (en) 2012-06-07
PL2796457T3 (pl) 2017-04-28
AU2016202591A1 (en) 2016-05-19
CR20120277A (es) 2012-09-05
EP2504332B2 (en) 2021-03-17
MX2012006083A (es) 2012-06-19
SMT201600273B (it) 2016-08-31
ECSP18063798A (es) 2020-02-28
ECSP12011926A (es) 2012-07-31
DK2504332T3 (da) 2014-08-25
KR20180049255A (ko) 2018-05-10
CY1115880T1 (el) 2017-01-25
CA3075788A1 (en) 2011-06-03
PL3133070T3 (pl) 2020-01-31
PT2504332E (pt) 2014-09-02
HRP20140780T4 (hr) 2021-08-06
DOP2012000141A (es) 2012-09-30
JP2016138124A (ja) 2016-08-04
TWI606827B (zh) 2017-12-01
US20210393590A1 (en) 2021-12-23
AU2017265180A1 (en) 2017-12-14
CA2781676C (en) 2020-05-05
TWI586663B (zh) 2017-06-11
PT3599237T (pt) 2021-04-28
RS59543B1 (sr) 2019-12-31
KR20150125734A (ko) 2015-11-09
JP2023116764A (ja) 2023-08-22
US20210369672A1 (en) 2021-12-02
ES2586947T3 (es) 2016-10-19
CA3140959A1 (en) 2011-06-03
JP6452635B2 (ja) 2019-01-16
CA2781676A1 (en) 2011-06-03
AU2016202591B2 (en) 2017-11-30
US20130137743A1 (en) 2013-05-30
CY1122698T1 (el) 2021-03-12
TW201737910A (zh) 2017-11-01
US20160166542A1 (en) 2016-06-16
ES2754398T3 (es) 2020-04-17
DK3133070T3 (da) 2019-11-11
TW201130822A (en) 2011-09-16
EP2796457B1 (en) 2016-05-18
IL283935A (en) 2021-07-29
EP2504332A1 (en) 2012-10-03
SI2796457T1 (sl) 2016-10-28
GT201200161A (es) 2014-01-27
US10888547B2 (en) 2021-01-12
KR102073207B1 (ko) 2020-02-05
MX358345B (es) 2018-08-14
WO2011066352A1 (en) 2011-06-03
AR121612A2 (es) 2022-06-22
PL2504332T5 (pl) 2021-08-23
BR112012012947B1 (pt) 2021-04-06
CN105753846B (zh) 2019-11-15
PH12015502514A1 (en) 2016-08-15
EP3599237B1 (en) 2021-03-24
IL219892A0 (en) 2012-07-31
HUE029371T2 (en) 2017-02-28
EA201270646A1 (ru) 2013-01-30
JP2019001809A (ja) 2019-01-10
EA023923B1 (ru) 2016-07-29
CN112521367B (zh) 2024-01-02
SG10201800136QA (en) 2018-02-27
JP6370264B2 (ja) 2018-08-08
CL2016002589A1 (es) 2017-05-19
DOP2016000250A (es) 2017-02-15
IL260299A (en) 2018-08-30
EP2796457A1 (en) 2014-10-29
AR079152A1 (es) 2011-12-28
US20160120842A1 (en) 2016-05-05
TW201639562A (zh) 2016-11-16
HRP20140780T1 (en) 2014-11-07
JP2020189873A (ja) 2020-11-26

Similar Documents

Publication Publication Date Title
IL283935A (en) Crystalline and amorphous form of genz 112638 hemitartrate as an inhibitor of glucosylceramide synthase
HK1254977A1 (zh) 索非布韋(sofosbuvir)的結晶形式
HK1200440A1 (zh) 種抑制劑的結晶形式
HRP20170214T1 (hr) Amorfna sol makrocikličkog inhibitora hcv
IL210322A0 (en) Crystalline salts of sitagliptin
EP2421867A4 (en) PANELID INHIBITORS OF JANUS KINASE 3
SI2155200T1 (sl) Kristalinična oblika kabamoil-cikloheksanskega derivata
PT2611779T (pt) Formas cristalinas de um inibidor do fator xa
IL221198A0 (en) Crystalline salts of a potent hcv inhibitor
HK1169408A1 (zh) 抑制劑的鹽類
SI2358676T1 (sl) Kristalinična oblika 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine
EP2439202A4 (en) INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1
ZA201104319B (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
HK1175780A1 (zh) 晶體 抑制劑鹽
HK1177459A1 (zh) 因子抑制劑的結晶鹽
AP2717A (en) Mono-hydrochloric salts of an inhibitor of histonedeacetylase
HUP0800755A2 (en) Crystalline forms of rosiglitazone
EP2488530A4 (en) INHIBITORS OF THE RENIN
EP2482821A4 (en) CRYSTALLINE HYDROCHLORIDE SALTS FROM C-MET KINASE INHIBITORS